Publications

February 2006 (Revised July 2007)
Case

Corporate Venture Capital at Eli Lilly

By: Richard G. Hamermesh, Ron Laufer and David Lane

Reviews the role of corporate venture capital and its history at Eli Lilly. Also presents a challenging venture investment opportunity. View Details

Keywords: Venture Capital; Investment; Pharmaceutical Industry

January 2006 (Revised May 2007)
Case

Endo Pharmaceuticals (A): From LBO to...?

By: Richard G. Hamermesh and Brian DeLacey

Endo Pharmaceuticals was formed in 1997 as a leveraged buyout spin-off from DuPont Merck. In 1999, it must decide whether to do an IPO or merge with a smaller company. View Details

Keywords: Private Equity; Initial Public Offering; Leveraged Buyouts; Mergers and Acquisitions; Health Care and Treatment; Pharmaceutical Industry; United States

January 2006 (Revised May 2007)
Supplement

Endo Pharmaceuticals (B): Merger Decision

By: Richard G. Hamermesh and Brian DeLacey

Keywords: Mergers and Acquisitions; Pharmaceutical Industry

January 2006 (Revised May 2007)
Supplement

Endo Pharmaceuticals (C): An "At Risk" Launch?

By: Richard G. Hamermesh and Brian DeLacey

Keywords: Product Launch; Risk and Uncertainty; Pharmaceutical Industry

January 2006 (Revised May 2007)
Supplement

Endo Pharmaceuticals (D): Hatch-Waxman Change

By: Richard G. Hamermesh and Brian DeLacey

Keywords: Change; Pharmaceutical Industry

January 2006 (Revised May 2007)
Supplement

Endo Pharmaceuticals (E): Judge Stein Rules

By: Richard G. Hamermesh and Brian DeLacey

Keywords: Lawsuits and Litigation; Pharmaceutical Industry

January 2006 (Revised May 2007)
Supplement

Endo Pharmaceuticals (F): Appeals Court Ruling

By: Richard G. Hamermesh and Brian DeLacey

Keywords: Lawsuits and Litigation; Pharmaceutical Industry

January 2006 (Revised July 2006)
Case

Drug Testing in Nigeria (A)

By: Debora L. Spar

In 1996, a meningitis epidemic swept across Nigeria. Thousands of children were struck and, lacking appropriate medicine, were liable to die from the disease. Doctors at Pfizer had an antibiotic that could probably save most of these children's lives. The drug was new,... View Details

Keywords: Risk and Uncertainty; Health Pandemics; Health Testing and Trials; Developing Countries and Economies; Pharmaceutical Industry; Nigeria

Article

Knowledge Spillovers, Geographic Location, and the Productivity of Pharmaceutical Research

By: Jeffrey Furman, Margaret K. Kyle, Iain Cockburn and Rebecca M. Henderson

Keywords: Geographic Location; Knowledge; Health; Research

Find at Harvard

Read Now

December 2005 (Revised August 2006)
Case

Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug

By: Felix Oberholzer-Gee and Dennis A. Yao

Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and... View Details

Keywords: Health Care and Treatment; Strategic Planning; Competition; Patents; Innovation and Invention; Pharmaceutical Industry; Pharmaceutical Industry; United States

November 2005 (Revised March 2006)
Case

Genentech - Capacity Planning

By: Daniel C. Snow, Steven C. Wheelwright and Alison Berkley Wagonfeld

While facilitating a complex clinical approval process over the next two to three years for a family of new cancer drugs, Genentech must develop a long-term capacity plan for a major class of new cancer products. Adding to the complexity and uncertainty is the fact... View Details

Keywords: Factories, Labs, and Plants; Growth and Development Strategy; Management Style; Management Teams; Time Management; Product; Product Development; Business Processes; Performance Capacity; Planning; Risk and Uncertainty; Complexity; Pharmaceutical Industry

September 2005 (Revised June 2006)
Case

WuXi PharmaTech

By: Richard G. Hamermesh and Simin Zhou

WuXi Pharmatech has gone from zero to $21 million in sales in three years. The company must decide its growth strategy and how best to finance and organize for rapid growth. View Details

Keywords: Growth Management; Capital Markets; Problems and Challenges; Pharmaceutical Industry; China

August 2005 (Revised December 2006)
Case

Procter & Gamble: Electronic Data Capture and Clinical Trial Management

By: Robert S. Huckman and Mark J. Cotteleer

Considers whether the management of Procter & Gamble (P&G) Pharmaceuticals should adopt Web-based electronic data capture (EDC) as the default standard for the management of its clinical drug trials. Provides a detailed description of the existing paper-based process... View Details

Keywords: Health Testing and Trials; Internet and the Web; Information Technology; Adoption; Business Processes; Industry Structures; Technological Innovation; Service Operations; Pharmaceutical Industry; United States

July 2005
Teaching Note

UCB: Managing Information for Globalization and Innovation (A)(TN)

By: F. Warren McFarlan

Teaching Note to (9-303-091). View Details

Keywords: Pharmaceutical Industry; Pharmaceutical Industry; Brussels

May 2005 (Revised April 2010)
Case

GlaxoSmithKline: Reorganizing Drug Discovery (A)

By: Robert S. Huckman and Eli Strick

Describes the reorganization of drug discovery at GlaxoSmithKline (GSK) following the formation of GSK from the merger of Glaxo Wellcome and SmithKline Beecham. This reorganization placed nearly 2,000 research scientists into six centers of excellence in drug discovery... View Details

Keywords: Mergers and Acquisitions; Decision Choices and Conditions; Operations; Organizational Structure; Performance Improvement; Research and Development; Pharmaceutical Industry

May 2005
Supplement

GlaxoSmithKline: Reorganizing Drug Discovery (B)

By: Robert S. Huckman and Eli Strick

Supplements the (A) case. View Details

Keywords: Mergers and Acquisitions; Decisions; Operations; Performance; Research and Development; Restructuring; Organizations; Pharmaceutical Industry